In addition to haematological AEs, ≥5% of patients experienced grade 3/4 ALT increase, creatinine phosphokinase increase, and fatigue with the two dosing schedules of trabectedin [22-26] and grade 3/4 asthenia with gemcitabine plus dacarbazine and dacarbazine monotherapy [20,21]. The gene discussed is GPT; the disease is asthenia.